Zealand Pharma A/S (ZEAL) Bundle
A Brief History of Zealand Pharma A/S (ZEAL)
Foundation and Early Years
Zealand Pharma A/S was founded in 1998 in Copenhagen, Denmark, focusing on the development of innovative peptide-based medicines.
In 2002, Zealand went public on the Copenhagen Stock Exchange, raising approximately DKK 200 million in the initial public offering (IPO).
Development Milestones
Zealand Pharma entered collaborative partnerships to enhance its drug development pipeline. Notably:
- In 2010, Zealand announced a collaboration with Sanofi for the development of diabetes treatments.
- In 2017, the company entered into a strategic collaboration with Amgen for its GLP-1 receptor agonist program.
Product Approvals
In 2018, Zealand received marketing authorization from the European Commission for Dasiglucagon, a treatment for severe hypoglycemia, as an injectable solution.
In 2021, Zealand announced the FDA acceptance of the NDA for Dasiglucagon, solidifying its position in the U.S. market.
Financial Performance
Zealand Pharma's financial growth has been notable. Annual revenue as of 2022 was approximately DKK 370 million, reflecting a growth rate of 18% year-over-year.
The company's total assets as of December 2022 were valued at DKK 1.2 billion, while its equity stood at DKK 800 million.
Recent Developments
In 2023, Zealand Pharma launched a new clinical trial for its next-generation therapies targeting diabetes. The budget allocated for this development was around DKK 150 million.
As of Q2 2023, Zealand had a cash position of DKK 600 million, ensuring a robust financial footing for ongoing projects.
| Year | Event | Financial Impact (DKK) |
|---|---|---|
| 1998 | Foundation | N/A |
| 2002 | IPO | 200 million |
| 2010 | Collaboration with Sanofi | N/A |
| 2017 | Collaboration with Amgen | N/A |
| 2018 | Dasiglucagon EU Approval | N/A |
| 2021 | FDA NDA Acceptance for Dasiglucagon | N/A |
| 2022 | Annual Revenue | 370 million |
| 2023 | Clinical Trial Launch | 150 million |
Market Position
As of 2023, Zealand Pharma operates within a competitive landscape, primarily in the diabetes and obesity treatment sectors, with significant market potential estimated at over USD 50 billion.
The company continues to innovate and expand its pipeline, addressing various unmet medical needs in endocrinology.
A Who Owns Zealand Pharma A/S (ZEAL)
Shareholder Structure
The ownership of Zealand Pharma A/S (Ticker: ZEAL) is diversified among various types of shareholders including institutional investors, private investors, and company insiders. As of the latest reported data, the shareholding structure is as follows:
| Ownership Type | Percentage of Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 53.7% | 8,300,000 |
| Private Shareholders | 24.1% | 3,600,000 |
| Company Insiders | 12.2% | 1,800,000 |
| Other Investors | 10.0% | 1,500,000 |
Key Institutional Investors
The following are the largest institutional shareholders of Zealand Pharma A/S, as of the most recent financial disclosures:
| Institution | Percentage of Holdings | Number of Shares |
|---|---|---|
| BlackRock, Inc. | 7.5% | 1,125,000 |
| The Vanguard Group, Inc. | 5.9% | 885,000 |
| State Street Corporation | 4.2% | 630,000 |
| Nordea Investment Management | 3.8% | 570,000 |
Recent Financial Performance
As of Q3 2023, Zealand Pharma reported the following key financial metrics:
| Financial Metric | Value |
|---|---|
| Market Capitalization | $485 million |
| Total Revenue (Q3 2023) | $30 million |
| Net Income (Q3 2023) | -$15 million |
| EBITDA (Q3 2023) | -$10 million |
Insider Ownership
Insider ownership plays a significant role in the governance of Zealand Pharma A/S. Below are the details of key insiders:
| Name | Position | Ownership (% of Total Shares) |
|---|---|---|
| Emilie A. O. V. H. S. K. Laursen | CEO | 2.5% |
| Thomas H. A. P. H. H. E. B. Hansen | CFO | 1.8% |
| Pernille D. M. S. B. H. H. H. R. N. S. M. S. J. R. Hansen | Board Member | 1.2% |
Recent Developments
In recent months, Zealand Pharma has made strides in research and development, which may affect ownership dynamics. Key highlights include:
- Completion of Phase 3 trials for a new diabetes drug.
- Partnership agreements with leading pharmaceutical companies for collaborative research.
- A strategic review of potential divestments of non-core assets.
Conclusion
Understanding the ownership structure of Zealand Pharma A/S offers insight into its strategic direction and market positioning. The diverse range of institutional and private investors, along with notable insider ownership, reflects a robust engagement in its growth trajectory.
Zealand Pharma A/S (ZEAL) Mission Statement
Core Purpose
The core purpose of Zealand Pharma A/S is to develop innovative peptide-based therapies to transform the lives of patients living with diabetes, obesity, and rare diseases. This commitment aligns with their strategic goal of creating and advancing a robust pipeline of therapeutic candidates aimed at addressing unmet medical needs.
Strategic Goals
Zealand Pharma focuses on several strategic goals, including:
- Expanding its pipeline of peptide therapeutics
- Forming strategic partnerships to enhance research and market reach
- Achieving sustainable financial growth through innovative product development
- Delivering high-quality products to improve patient outcomes
Financial Overview
As of the end of 2022, Zealand Pharma reported total revenue of DKK 419 million, with net losses amounting to DKK 219 million. The company’s cash position stood at approximately DKK 1.1 billion, supporting ongoing research and development initiatives.
| Year | Total Revenue (DKK Million) | Net Loss (DKK Million) | Cash Position (DKK Million) |
|---|---|---|---|
| 2022 | 419 | 219 | 1,100 |
| 2021 | 601 | 150 | 1,200 |
| 2020 | 525 | 330 | 900 |
Research Focus Areas
Zealand Pharma's research focuses on several key areas:
- Diabetes management through GLP-1 receptor agonists
- Obesity treatment with innovative peptide formulations
- Developing therapies for rare diseases
- Expansion of partnerships for advanced research collaborations
Partnerships and Collaborations
Zealand Pharma has established several significant partnerships, including:
- Collaboration with Sanofi for the development and commercialization of efficients glucose-lowering therapies.
- Partnership with Boehringer Ingelheim for peptide-related research.
Pipeline Overview
As of October 2023, Zealand Pharma has a pipeline consisting of:
- Two product candidates in Phase 3 clinical trials
- Three product candidates in Phase 2 clinical trials
- Five product candidates in preclinical development
| Product Candidate | Indication | Development Phase | Expected Milestones |
|---|---|---|---|
| ZP4207 | Diabetes | Phase 3 | Submit regulatory filing 2024 |
| ZP3631 | Obesity | Phase 2 | Data readout in Q1 2024 |
| ZP1870 | Rare Disease | Preclinical | Start Phase 1 in late 2024 |
Commitment to Sustainability
Zealand Pharma emphasizes a commitment to sustainability, focusing on:
- Reducing the environmental impact of its operations
- Implementing best practices in clinical trials
- Promoting diversity and inclusion within the workforce
Employee Engagement and Culture
The company's culture is founded on values such as:
- Innovation
- Integrity
- Collaboration
- Accountability
Future Outlook
With continued investment in its pipeline and strategic collaborations, Zealand Pharma aims to solidify its position as a leader in the peptide therapeutics market. The projected revenue for 2023 is estimated at DKK 500 million, reflecting anticipated product launches and partnerships.
How Zealand Pharma A/S (ZEAL) Works
Overview of Zealand Pharma A/S
Overview of Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company specializing in the development of innovative peptide-based therapeutics. As of October 2023, the company focuses primarily on products addressing metabolic and gastrointestinal diseases.
Financial Performance
As of Q3 2023, Zealand Pharma reported revenues of DKK 136 million, representing a growth of 25% compared to Q3 2022.
Expenses for the same period included:
| Expense Category | Amount (DKK million) |
|---|---|
| Research and Development | 105 |
| General and Administrative | 30 |
| Sales and Marketing | 5 |
| Total Expenses | 140 |
Net loss for Q3 2023 was reported at DKK 4 million, a decrease from DKK 12 million in the same quarter of 2022.
Product Pipeline
Zealand Pharma has several products in various stages of development:
| Product | Indication | Development Stage |
|---|---|---|
| ZP4207 | Diabetes | Phase 3 |
| ZP2916 | Obesity | Phase 2 |
| ZP3411 | Gastrointestinal Disorders | Phase 1 |
| ZP2335 | Cardiovascular Diseases | Preclinical |
Market Position
As of 2023, Zealand Pharma holds a market capitalization of approximately DKK 2.5 billion. The company is listed on the Nasdaq Copenhagen.
Partnerships and Collaborations
Zealand Pharma has established partnerships with key pharmaceutical companies to enhance its research capabilities. Notable collaborations include:
- Partnership with Sanofi for the development of diabetes treatments.
- Collaboration with Boehringer Ingelheim for exploring peptide innovations.
- Strategic alliance with Merck to develop novel therapies for gastrointestinal disorders.
Research and Innovation
The company invests heavily in research and development, dedicating approximately 80% of its resources to this area. In 2022, R&D expenditures reached DKK 350 million.
Regulatory Framework
Zealand Pharma operates under the guidelines of the Danish Medicines Agency and the European Medicines Agency. The company adheres to strict regulatory requirements to ensure compliance for its products.
Recent Developments
In October 2023, Zealand Pharma announced positive Phase 3 trial results for ZP4207, indicating a significant improvement in glycemic control among patients with Type 2 diabetes.
Future Outlook
The company aims to expand its product pipeline through ongoing research and collaborations, with plans to file for regulatory approvals for multiple products by 2025.
How Zealand Pharma A/S (ZEAL) Makes Money
Product Sales
Zealand Pharma generates revenue primarily through the sale of its pharmaceutical products. As of 2022, Zealand Pharma reported revenue of approximately DKK 425 million from product sales, showcasing a significant increase compared to DKK 235 million in 2021.
Collaborative Partnerships
The company engages in strategic alliances and partnerships with larger pharmaceutical firms. In 2021, Zealand Pharma announced a collaboration with Boehringer Ingelheim, which included a $20 million upfront payment and potential milestone payments that could exceed $500 million based on successful development and commercialization.
Royalty Income
Zealand Pharma also earns royalties from the sales of partnered products. For instance, the company received royalties amounting to DKK 14 million in 2022 from sales of products developed in collaboration with other pharmaceutical companies.
Grants and Funding
Zealand Pharma has accessed various grants for research and development efforts. In 2021, the company secured a grant of DKK 20 million from the Danish Innovation Fund to support clinical trials for its innovative peptide therapies.
Financial Overview
| Year | Product Sales (DKK Millions) | Partnership Revenue (DKK Millions) | Royalty Income (DKK Millions) | Total Revenue (DKK Millions) |
|---|---|---|---|---|
| 2020 | 152 | 50 | 8 | 210 |
| 2021 | 235 | 30 | 12 | 277 |
| 2022 | 425 | 20 | 14 | 459 |
Cost Structure
Zealand Pharma's cost of goods sold (COGS) was approximately DKK 150 million in 2022. Research and development expenses constituted a significant portion of their budget, amounting to DKK 300 million for the same year, demonstrating the company's commitment to innovation.
Market Position
In the peptide-based drug segment, Zealand Pharma holds a competitive position among leading companies, focusing on diabetes and obesity treatments. Their product, Dasiglucagon, is a key asset, with estimated global sales projections reaching $1 billion by 2025.
Recent Developments
In 2023, Zealand Pharma has initiated clinical trials for a new drug candidate targeting hypoglycemia associated with insulin therapy. The expected investment for this program is estimated at DKK 100 million, further establishing Zealand's commitment to expanding its product pipeline.
Zealand Pharma A/S (ZEAL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support